If approved, KEYTRUDA would be the first immunotherapy for the first-line treatment of HER2-positive advanced gastric or GEJ cancer in tumors expressing PD-L1 (CPS ?1) in the EU
Mage Biologics to develop a monoclonal antibody targeting ulcerative colitis
Approval to dramatically change CAR-T therapies landscape
Marketing Authorization replaces conditional Marketing Authorization and is first for Novavax in the EU
Especially valuable for young patients with multiple blocks & underlying conditions that may render angioplasty procedures with drug-eluting stents ineffective
Collaboration to provide hospitals with a comprehensive offering across imaging and treatment for cancer patients requiring radiation therapy
Cipla has a robust governance model focused on sustainability
Rapid card test kits for iScreen malaria card antigen (Pf/Pv) & iScreen dengue NS1
New reforestation projects in Brazil, India, Vietnam, Ghana and Rwanda in addition to existing projects including in Australia and Indonesia
Survodutide has a novel mechanism of action (agonism of the dual GCG/GLP-1 receptors) that may have direct effects on energy expenditure in the liver in addition to decreasing appetite
Subscribe To Our Newsletter & Stay Updated
